Singapore markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
12.49+0.40 (+3.31%)
At close: 4:00PM EDT
Sign in to post a message.
  • T
    TRILLIUM
    Not too familiar with ESPR & it’s drug BA. But know very well about the terrible side effects of statins.

    Yesterday I listened to the webcast with Dr S. Nissen & wasn’t surprised to learn that the FDA approved Statin Trials did not include Statin Intolerance Patients. And that’s why many cardiologists/family physicians are totally unaware of the statin side effects. Obviously an alternative is badly needed & based on what I heard from Dr Nissen, BA might do the job!

    The question I have is with regard to the company share price, which has been dripping continuously from a high of about $70 to where it is today during the past 18 months or so…

    Does anyone who has been following the company knows what the hidden reason or reasons for share price depreciation might be?
    Dilution doesn’t appear to be the reason as the shares outstanding is under 30M!
  • R
    Ross
    Dr. Nissen is the lead investigator on the CVOT trial. This webinar was very informative. Research analyst were engaged and asked great questions. If ESPR can bridge operations through the CVOT , Dr. Nissen seems very optimistic (but keeps emphasizing he is neutral as an investigator- which he should be) that BA will be broadly adopted by physicians and payors. He provided many case studies and empirical data to suggest CVOT and BA’s future looks bright. Fingers crossed!!! Sheldon don’t F-things up. Dr. Nissen just put a floor in the stock price for the time being .
  • D
    Darvin
    can this thing double by end of year? thumbs up for yes, down for no :)
  • R
    Ross
    JMP Research Post Webinar with Dr. Nissen
    Esperion Therapeutics, Inc.
    KOL Event Primes the Pump for Outcomes Data
    Jason N. Butler, PhD
    Roy Buchanan, PhD
    ESPR: $11.38 | Market Cap: $322.1 | MARKET OUTPERFORM | Price Target: $90.00

    Discussion with Dr. Steven Nissen provides long-term confidence in the blockbuster potential of the bempedoic acid franchise; we reiterate our Market Outperform rating and risk-adjusted, DCF-derived $90 price target on Esperion Therapeutics. Dr. Nissen is a renowned cardiovascular expert and lead investigator on the CLEAR Outcomes cardiovascular outcomes trial (CVOT) for bempedoic acid. Dr. Nissen focused on the unmet need for the largest driver of mortality in the developed world, cardiovascular disease. In his view, bempedoic acid is an important drug for the ~50% of people, 35MM-40MM, in the U.S. that meet criteria for lipid lowering medications but do not take them. He expressed optimism for success in the CLEAR Outcomes trial (results from CLEAR Outcomes remains on track for ~1 year from now) given the validation of LDL-C as a biomarker and pointed to the drug’s impact on inflammation and glucose control as differentiating attributes.
    Key points:
    Dr. Steven Nissen, M.D. is the Chief Academic Officer of the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at the Cleveland Clinic and he has deep experience in the conduct of CV trials, and particularly CVOTs. He has extensively advocated for lower LDL as an objective goal to improve outcomes and also believes that statin intolerance is a real issue with many patients, as he has observed in real-world practice.
    Stain intolerance is real, and the unmet need for better LDL-C control is high. Dr. Nissen believes that statin intolerance is a key impediment to better LDL-C control given patients’ unwillingness to take statins chronically with high compliance. He pointed to a lack of prescriber education on the real-world impact of statin intolerance and the limitations (selection bias) of pointing to historical statin trials as a counter to the importance of statin intolerance. Specifically he noted that statin CVOTs did not have many statin intolerant patients because they were screened out due to having a statin run-in phase, which can create the false impression of fewer statin intolerant patients in the broader population. He acknowledged FDA’s struggles with the patient population, in part due to lack of a biomarker.
    CLEAR Outcomes is well designed, evaluating a population that provides the best potential for success, and has not been impacted by the COVID-19 pandemic. Dr. Nissen has been impressed with the ability of CLEAR Outcomes to stay on schedule despite the COVID-19 pandemic, testament to the efforts of Esperion, Cleveland Clinic, and the CRO. Key metrics such as patient retention, drop-out rate, and event rate have all tracked to expectations set well before the pandemic emerged.
  • j
    james
    I don't know why anyone believes ESPR is flirting with the bottom. Listening to management spin on these calls tells you a far different story. Summary of call as follows:

    1. Everything is wonderful and everyone at the company is wonderful. We are getting a fantastic reaction from the healthcare community and everyone now understands where this wonderful drug should be prescribed.

    2. We're not getting any new prescriptions since the Q2 earnings call. People must not be going to the doctors.

    3. We're keenly aware that we are running out of cash at lightening speed but have no concrete plan to finance our huge burn rate.

    4. We'll have some concrete proof that our drug works (we think) as early as just 10 months after we run out of cash.

    5. We're excited and everything is wonderful.
  • k
    kenm
    Was hoping it would reach 10.75 over time but i think it has found reasonable support level.
    Positive earnings starting to mushroom.
    TIME TO BUY!
  • M
    MaryM
    Hi short interest with 15 days to cover. The article about “flirting with the bottom“ and upcoming conference call makes this a prime target for a significant up move. I bought today. Crossing my fingers.
  • c
    ctic_neutral
    One of the best bargains I've ever seen. NOVEL (with different mechanism of action from statins) effective FDA-approved cholesterol medicine. Double the float with a MASSIVE offering and you still have a pittance $700M market cap for a compound that will eventually have sales of at least a Billion a year - and MORE if BP acquires or partners.

    Evaporated 1/4 of my DVAX position on it's run up (more in the tank there IMO), and redeployed some here. bringing my position to 4K shrs cost avg $20.70. Long term HOLD.
  • E
    Edward
    JMP Research Post Webinar with Dr. Nissen
    Esperion Therapeutics, Inc. (ESPR): $11.38 | Market Cap: $322.1 | MARKET OUTPERFORM | Price Target: $90.00
    KOL Event Primes the Pump for Outcomes Data
    Jason N. Butler, PhD
    Roy Buchanan, PhD
  • E
    Edward
    1 of 3 "Strong Buy" Stocks Flirting with a Bottom
  • E
    Edward
    Chief Medical Officer, Dr. Foody and Dr. Nissen, will discuss the current landscape and future directions in the treatment of elevated cholesterol in an Analyst & Investor Webinar to be held on September 13 at 1:30 pm.
  • M
    MaryM
    Low float, high short interest with 14 days to cover, bottomed, increased volume. 😉
  • E
    Edward
    It is also strange that almost no one pays attention to the comments of some health workers that overweight people (who have obvious problems with bad cholesterol) are more seriously worse with COVID-19, and also that the virus is most likely related to thrombosis. Perhaps it makes sense to conduct some research on this, suddenly the inclusion of bempedoic acid in the complex treatment of COVID-19 will help reduce mortality. Such a fact could greatly accelerate the promotion of the company's drugs.
  • E
    Edward
    ANN ARBOR, Mich., (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the lipid management company, will host an investor webinar on the current landscape and future directions in the treatment of elevated cholesterol on Monday, September 13, 2021 at 1:30pm Eastern Time.
  • G
    Gary9912
    Dr. Nissen was confident but neutral today as he mentioned several times (he would have to be neutral, of course) and he’s way more popular and respected than yours and my cardiologists, he’s among the nation’s best, hopefully those analysts asking questions can digest the information and come out with some new price targets.

    https://www.acls.net/2013/05/15/the-10-most-highly-regarded-heart-doctors-in-the-us

    https://www.google.com/amp/s/www.forbes.com/sites/matthewherper/2017/12/05/27-top-cardiologists-picked-by-big-data/amp/

    https://www.dicardiology.com/content/dr-steven-e-nissen-named-one-time-magazines-100-most-influential-people
    The 10 Most Highly Regarded Heart Doctors in the US
    www.acls.net
  • A
    Andrew
    The spring has already compressed to a critical point, it will shoot soon.
  • Y
    Yahoo User
    $NKTR conversation
    kurt11 hours ago
    $NKTR conversation
    ChartMill
    @ChartMill
    ·
    31m
    Most gaining stocks in the Russel 2000 today: $ESPR,
  • E
    Edward
    1 of Top-5 consumer discretionary stocks most shorted right now.
  • k
    kurt
    $NKTR conversation
    ChartMill
    @ChartMill
    ·
    31m
    Most gaining stocks in the Russel 2000 today: $ESPR,
  • s
    smith
    Bitcoin is the future! Many people are seeking for stability in this unstable crypto space and A lot of people are wondering if now is a good time to buy because of where the price is at right now . I'd say it's outrightly wrong to just sit back hold and wait maybe incur some losses along the line , that's a wrong mindset for an investor because as an investor finding ways to always increase and stack up more coins thereby making proflts should be the way of life that being said , the market is still all about BTC at the moment and I'll advise current investors and newbies to take advantage of the Mr Steve program , an establishment that handles people who lack understanding on how maneuver the crypto space , to help them recover loss from the crash and also accumulate more positive returns , with their program i went from having 1.4btc to 9btc in just 9 weeks. Steve can be reached on TELEG.RAM ( stevewarrenfx ) or on WhatsApp: +1 (813) 683‑ 6310